Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Sees Significant Increase in Short Interest

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) was the target of a large increase in short interest during the month of November. As of November 30th, there was short interest totalling 1,500,000 shares, an increase of 93.6% from the November 15th total of 774,700 shares. Currently, 6.7% of the shares of the company are short sold. Based on an average daily trading volume, of 16,110,000 shares, the days-to-cover ratio is currently 0.1 days.

Insiders Place Their Bets

In other news, insider Neal Flomenberg sold 1,078,600 shares of the firm’s stock in a transaction on Thursday, October 17th. The stock was sold at an average price of $1.62, for a total value of $1,747,332.00. Following the transaction, the insider now directly owns 4,254,302 shares in the company, valued at $6,891,969.24. This trade represents a 20.23 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. 56.60% of the stock is owned by insiders.

Institutional Trading of Tevogen Bio

An institutional investor recently bought a new position in Tevogen Bio stock. HGC Investment Management Inc. acquired a new stake in shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 223,077 shares of the company’s stock, valued at approximately $82,000. HGC Investment Management Inc. owned 0.13% of Tevogen Bio at the end of the most recent quarter.

Tevogen Bio Stock Down 1.0 %

TVGN stock traded down $0.01 during midday trading on Friday, reaching $1.00. 850,593 shares of the company’s stock traded hands, compared to its average volume of 4,787,343. Tevogen Bio has a 52-week low of $0.26 and a 52-week high of $21.09. The stock’s 50-day moving average is $1.45 and its 200 day moving average is $0.91.

About Tevogen Bio

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.